Homegrown specialty pharmaceutical company iX Biopharma is pleased to announce that it has been granted a European patent (no. 2493457) for its WaferiX drug delivery technology.
Singapore, 23 October 2017 – Homegrown specialty pharmaceutical company iX Biopharma (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce that it has been granted a European patent (no. 2493457) for its WaferiX drug delivery technology. The grant allows iX Biopharma to obtain validation and coverage in the countries that currently make up the EU. For a start, iX Biopharma has proceeded to apply for coverage in 16 of these countries, namely Germany, France, United Kingdom, Italy, Spain, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, Austria, Norway, Denmark, Ireland and Finland.
WaferiX is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream.
iX Biopharma employs the WaferiX technology in the development of innovative therapies that improve the quality of life. The technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips, injections and oral intake. Key advantages of WaferiX include the reduction of the effect of first-pass metabolism, rapid onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile.
The WaferiX technology is used to develop many of the products in iX Biopharma’s pipeline. Wafermine, its lead pharmaceutical product, leverages the sublingual platform to incorporate ketamine and is being developed for the management of moderate to severe pain. The Group has also recently launched WafeRest, a sublingual melatonin wafer supplement, in Singapore.
Apart from the EU, iX Biopharma has also secured patents in nine other countries including Singapore, Australia, New Zealand, Malaysia, Indonesia, South Korea, Japan, Canada and South Africa. The patent will expire on 26 October 2030.
About iX Biopharma Ltd iX Biopharma Ltd is a Singapore public-listed specialty pharmaceutical company, operating a fully integrated business model from drug development to laboratory testing, manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of innovative therapies for improving the quality of life of those suffering from pain and other health conditions. The Company leverages its patented sublingual drug delivery technology, WaferiX, to develop proprietary products that incorporate pharmacologically active compounds that have been approved by regulatory bodies. It recently launched WafeRest, for improved sleep quality. Its pipeline of products under development includes Wafermine and BnoX for pain management and PheoniX for erectile dysfunction. The Group’s nutraceuticals division, Entity Health Limited, is engaged in development and commercialisation of nutraceutical products that address specific conditions and improve quality of life.
